Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Esketamine/Palliative & End-of-Life Distress

Esketamine for Palliative & End-of-Life Distress

2 papers and 0 clinical trials exploring esketamine as a treatment for palliative & end-of-life distress.

Compounddissociative

Esketamine

Esketamine (Spravato) is the S-enantiomer of ketamine, approved as an intranasal treatment for treatment-resistant depression and MDD with acute suicidal ideation. It is administered under clinical supervision with post-dose monitoring and has reached over $1.6 billion in annual sales.

Full Esketamine profile
IndicationApproximately 40% of patients with terminal illnesses report significant distress at the end of life.

Palliative & End-of-Life Distress

Palliative and end-of-life distress represents a significant psychosocial challenge faced by patients with life-limiting illnesses, significantly impacting quality of life. Recent research suggests that psychedelic compounds, particularly psilocybin, may offer promising therapeutic benefits in alleviating existential distress and improving psychological well-being in these patients.

Full Palliative & End-of-Life Distress profile

Academic Research

2 papers
Paywallindividual

Efficacy and safety of esketamine for smoking cessation among patients diagnosed with lung cancer and major depression disorder: A randomized, placebo-controlled clinical trial

This multicenter, randomised, placebo-controlled clinical trial (n=236) investigates the efficacy and safety of esketamine (ESK) (8x35mg) for smoking cessation in patients with lung cancer and major depressive disorder (MDD). Eight weekly intranasal ESK sessions significantly improved both self-reported (44.1%) and biologically verified (28.8%) smoking abstinence at 6-month follow-up, alongside reductions in depression, anxiety, nicotine dependence, and respiratory symptoms.

Published
August 1, 2025
Journal
Journal of Affective Disorders
Authors
Hong, C. J.
Paywallindividual

A rapid positive influence of S-ketamine on the anxiety of patients in palliative care: a retrospective pilot study

A retrospective pilot study of eight palliative care patients given an intravenous S-ketamine infusion (0.25 mg/kg) found a rapid, significant reduction in anxiety compared with matched controls, with no significant change in depression or lasting analgesic effects. Findings are limited by the small, non-randomised retrospective design and need confirmation in prospective randomised trials.

Published
January 3, 2020
Journal
BMC Palliative Care
Authors
Falk, E., Schlieper, D., Van Caster, P., Lutterbeck, M. J., Schwartz, J., Cordes, J., Grau, I., Kienbaum, P., Neukirchen, M.

Clinical Trials

0 trials

No clinical trials have been tagged with both Esketamine and Palliative & End-of-Life Distress yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Esketamine papers Search all Palliative & End-of-Life Distress trials Full Esketamine profile Full Palliative & End-of-Life Distress profile